PDCD1 and metastatic melanoma: Both of these checkpoint inhibitors are highly enriched in CD103+ tumour-resident CD8+ T-cells in untreated metastatic melanoma patients, suggesting that these cells are likely to be the initial target of anti-PD-1 treatment.